Socionext (6526) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
31 Oct, 2026Executive summary
FY24 net sales rose 14.8% to ¥221,246 million; operating income increased 63.6% to ¥35,510 million and profit attributable to owners of parent rose 32.2% to ¥26,134 million.
Growth reflected higher product revenue, improved product cost ratio and yen depreciation; FY25 guidance anticipates lower sales and earnings.
Financial highlights
Product revenue rose 16.7% to ¥182,876 million; NRE revenue increased 7.9% to ¥37,609 million.
Gross profit was ¥110,003 million versus ¥88,845 million; cost of sales rose 7.0% to ¥111,243 million, below sales growth.
R&D costs increased 8.0% to ¥53,279 million; SG&A rose 11.0% to ¥74,493 million.
Yen depreciation added ¥11.7 billion to sales and ¥2.5 billion to operating income YoY; average rate was ¥144.6 per U.S. dollar.
Q4 net sales declined 4.3% YoY to ¥51.6bn; operating income increased 52.4% to ¥7.6bn, with a 14.7% margin.
Outlook and guidance
FY25 forecast: net sales ¥200,000 million, down 9.6%; operating income ¥27,000 million, down 24.0%; profit attributable to owners of parent ¥19,500 million, down 25.4%.
FY25 basic EPS forecast is ¥109.13; dividend guidance is ¥50 per share versus FY24 actual ¥48; forecast exchange rate is ¥130 per U.S. dollar.
New mass production is expected to represent 10% of FY25 product sales, but product revenue is forecast flat to slightly lower in real terms as special demand ends.
FY26 sales may remain at FY25 levels or slightly lower; growth is expected from FY27 as design-win projects enter mass production, with an operating margin target in the mid-to-high teens.
Latest events from Socionext
- Higher FY2027 guidance contrasts with H1 profit declines and product-margin pressure.6526
Q2 2027 - Net sales rose 13% YoY, but higher costs led to operating and net losses.6526
Q1 2027 - Net sales up 6.5% YoY, but profit fell; FY27 outlook expects renewed growth.6526
Q4 2026 - Sales rebounded, but profits and margins remain pressured by costs and FX; guidance unchanged.6526
Q3 2026 - Sales guidance raised but profit outlook cut as margins shrink amid higher costs and weak demand.6526
Q2 2026 - Sharp profit and sales drop in 1Q FY26/3, but full-year guidance and recovery outlook are maintained.6526
Q1 2026 - Sales and profit fell, but R&D and NRE revenue rose; treasury stock buyback approved.6526
Q2 2025 - Net sales fell 14.1% but operating income and R&D investment both increased.6526
Q1 2025 - Revenue and profit fell sharply, but investments and design wins support future growth.6526
Q4 2025